These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27699717)

  • 21. The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Visanji NP; de Bie RM; Johnston TH; McCreary AC; Brotchie JM; Fox SH
    Mov Disord; 2008 Oct; 23(13):1922-5. PubMed ID: 18759357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progressive changes of pre- and post-synaptic dopaminergic biomarkers in conscious MPTP-treated cynomolgus monkeys measured by positron emission tomography.
    Nagai Y; Obayashi S; Ando K; Inaji M; Maeda J; Okauchi T; Ito H; Suhara T
    Synapse; 2007 Oct; 61(10):809-19. PubMed ID: 17598150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fine Manual Dexterity Assessment After Autologous Neural Cell Ecosystem (ANCE) Transplantation in a Non-human Primate Model of Parkinson's Disease.
    Borgognon S; Cottet J; Moret V; Chatagny P; Carrara L; Fregosi M; Bloch J; Brunet JF; Rouiller EM; Badoud S
    Neurorehabil Neural Repair; 2019 Jul; 33(7):553-567. PubMed ID: 31170868
    [No Abstract]   [Full Text] [Related]  

  • 24. Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot study.
    Huot P; Johnston TH; Fox SH; Brotchie JM
    Synapse; 2015 Mar; 69(3):99-102. PubMed ID: 25559284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo NMR studies of regional cerebral energetics in MPTP model of Parkinson's disease: recovery of cerebral metabolism with acute levodopa treatment.
    Bagga P; Chugani AN; Varadarajan KS; Patel AB
    J Neurochem; 2013 Nov; 127(3):365-77. PubMed ID: 23957451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets.
    Johnston LC; Jackson MJ; Rose S; McCreary AC; Jenner P
    Mov Disord; 2010 Oct; 25(13):2059-66. PubMed ID: 20721904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery.
    Mounayar S; Boulet S; Tandé D; Jan C; Pessiglione M; Hirsch EC; Féger J; Savasta M; François C; Tremblay L
    Brain; 2007 Nov; 130(Pt 11):2898-914. PubMed ID: 17855373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate.
    Beaudoin-Gobert M; Epinat J; Météreau E; Duperrier S; Neumane S; Ballanger B; Lavenne F; Liger F; Tourvielle C; Bonnefoi F; Costes N; Bars DL; Broussolle E; Thobois S; Tremblay L; Sgambato-Faure V
    Brain; 2015 Sep; 138(Pt 9):2632-47. PubMed ID: 26117365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of nicotinic therapies on attention and executive functions in chronic low-dose MPTP-treated monkeys.
    Decamp E; Schneider JS
    Eur J Neurosci; 2006 Oct; 24(7):2098-104. PubMed ID: 17067307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications.
    Morin N; Morissette M; Grégoire L; Rajput A; Rajput AH; Di Paolo T
    Neuropharmacology; 2015 Dec; 99():356-68. PubMed ID: 26254863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys.
    Morin N; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2010 Jun; 58(7):981-6. PubMed ID: 20074579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel adenosine A(1) and A(2A) receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: comparison with existing anti-Parkinson's disease drugs.
    Mihara T; Iwashita A; Matsuoka N
    Behav Brain Res; 2008 Dec; 194(2):152-61. PubMed ID: 18657577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.
    Tayarani-Binazir KA; Jackson MJ; Rose S; Olanow CW; Jenner P
    Mov Disord; 2010 Feb; 25(3):377-84. PubMed ID: 20108359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protective action of recombinant neurturin on dopaminergic neurons in substantia nigra in a rhesus monkey model of Parkinson's disease.
    Li H; He Z; Su T; Ma Y; Lu S; Dai C; Sun M
    Neurol Res; 2003 Apr; 25(3):263-7. PubMed ID: 12739234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The MPTP mouse model: cues on DA release and neural stem cell restorative role.
    Serra PA; Pluchino S; Marchetti B; Desole MS; Miele E
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S189-93. PubMed ID: 18579428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The combination of lithium and l-Dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: Relevance for Parkinson׳s disease therapy.
    Lazzara CA; Riley RR; Rane A; Andersen JK; Kim YH
    Brain Res; 2015 Oct; 1622():127-36. PubMed ID: 26119916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A quantitative approach to developing Parkinsonian monkeys (Macaca fascicularis) with intracerebroventricular 1-methyl-4-phenylpyridinium injections.
    Li H; Lei X; Huang B; Rizak JD; Yang L; Yang S; Wu J; Lü L; Wang J; Yan T; Li H; Wang Z; Hu Y; Le W; Deng X; Li J; Xu L; Zhang B; Hu X
    J Neurosci Methods; 2015 Aug; 251():99-107. PubMed ID: 26003862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
    Morin N; Grégoire L; Morissette M; Desrayaud S; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cortical Phase-Amplitude Coupling in a Progressive Model of Parkinsonism in Nonhuman Primates.
    Devergnas A; Caiola M; Pittard D; Wichmann T
    Cereb Cortex; 2019 Jan; 29(1):167-177. PubMed ID: 29190329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.